Fiche société
David Porter
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| KYV-101The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years. | Lupus, Myasthénie | Phase 1 | Immunomodulation + Thérapie cellulaire | United States | À vérifier |
| KYV-101The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years. | Lupus | Phase 1 | Immunomodulation + Thérapie cellulaire | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| KYV-101 | Lupus | Phase 1 | NCT06152172 | CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | ACTIVE_NOT_RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| KYV-101 | CAR-engineered cell therapies: current understandings and future perspectives. | Molecular biomedicine | ||
| KYV-101 | Neutrophil transcriptomics in SLE reveals intrinsic disease signatures, shared ex vivo adaptation, and transcriptional reset after CAR T-cell therapy. | Annals of the rheumatic diseases | ||
| KYV-101 | A new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report. | Rheumatology (Oxford, England) |